This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Review

. 2005 Jun;6(1):50-1.

doi: 10.3816/clm.2005.n.028.

ABVD, the Stanford V regimen, and BEACOPP for Hodgkin's lymphoma: what should an oncologist do?

Joseph M Connors¹

Affiliations

PMID: 15989708
DOI: 10.3816/clm.2005.n.028

Review

ABVD, the Stanford V regimen, and BEACOPP for Hodgkin's lymphoma: what should an oncologist do?

Joseph M Connors. Clin Lymphoma. 2005 Jun.

. 2005 Jun;6(1):50-1.

doi: 10.3816/clm.2005.n.028.

Author

Joseph M Connors¹

Affiliation

¹ Lymphoma Tumor Group British Columbia Cancer Agency and the University of British Columbia Vancouver, BC, Canada.

PMID: 15989708
DOI: 10.3816/clm.2005.n.028

No abstract available

PubMed Disclaimer

Comment on

9th Annual International Congress on Hematologic Malignancies, Whistler, BC, Canada; 41st Annual Meeting of the American Society of Clinical Oncology, Orlando, FL; 46th Annual Meeting of the American Society of Hematology, San Diego, CA.
Reddy GK, Tyagi P. Reddy GK, et al. Clin Lymphoma. 2005 Jun;6(1):4-10. doi: 10.1016/s1526-9655(11)70110-5. Clin Lymphoma. 2005. PMID: 15989700 No abstract available.

Similar articles

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.
Viviani S, Zinzani PL, Rambaldi A, Brusamolino E, Levis A, Bonfante V, Vitolo U, Pulsoni A, Liberati AM, Specchia G, Valagussa P, Rossi A, Zaja F, Pogliani EM, Pregno P, Gotti M, Gallamini A, Rota Scalabrini D, Bonadonna G, Gianni AM; Michelangelo Foundation; Gruppo Italiano di Terapie Innovative nei Linfomi; Intergruppo Italiano Linfomi. Viviani S, et al. N Engl J Med. 2011 Jul 21;365(3):203-12. doi: 10.1056/NEJMoa1100340. N Engl J Med. 2011. PMID: 21774708 Clinical Trial.
Feasibility of upfront dose-intensive chemotherapy in children with advanced-stage Hodgkin's lymphoma: preliminary results from the Children's Cancer Group Study CCG-59704.
Kelly KM, Hutchinson RJ, Sposto R, Weiner MA, Lones MA, Perkins SL, Massey V; Children's Oncology Group. Kelly KM, et al. Ann Oncol. 2002;13 Suppl 1:107-11. doi: 10.1093/annonc/13.s1.107. Ann Oncol. 2002. PMID: 12078889 Clinical Trial.
Secondary amenorrhea after Hodgkin's lymphoma is influenced by age at treatment, stage of disease, chemotherapy regimen, and the use of oral contraceptives during therapy: a report from the German Hodgkin's Lymphoma Study Group.
Behringer K, Breuer K, Reineke T, May M, Nogova L, Klimm B, Schmitz T, Wildt L, Diehl V, Engert A; German Hodgkin's Lymphoma Study Group. Behringer K, et al. J Clin Oncol. 2005 Oct 20;23(30):7555-64. doi: 10.1200/JCO.2005.08.138. J Clin Oncol. 2005. PMID: 16234521
Prophylactic use of filgrastim with ABVD and BEACOPP chemotherapy regimens for Hodgkin lymphoma.
Wedgwood A, Younes A. Wedgwood A, et al. Clin Lymphoma Myeloma. 2007 Dec;8 Suppl 2:S63-6. doi: 10.3816/clm.2007.s.035. Clin Lymphoma Myeloma. 2007. PMID: 18284718 Review.
Comparison of the efficiency of ABVD versus BEACOPP for Hodgkin lymphoma treatment: a meta-analysis.
Jiang Y, Chen Y, Huang R, Chen G. Jiang Y, et al. Int J Hematol. 2016 Oct;104(4):413-9. doi: 10.1007/s12185-016-2080-5. Epub 2016 Aug 16. Int J Hematol. 2016. PMID: 27531149 Review.

See all similar articles

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Supplementary concepts

Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
- Ovid Technologies, Inc.
Medical
- MedlinePlus Health Information